These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 8393313)
1. [New antifungal agents in the treatment of superficial dermatomycoses]. Degreef H Ann Dermatol Venereol; 1993; 120(1):21-31. PubMed ID: 8393313 [TBL] [Abstract][Full Text] [Related]
2. Current concepts in systemic and topical therapy for superficial mycoses. Millikan LE Clin Dermatol; 2010 Mar; 28(2):212-6. PubMed ID: 20347665 [TBL] [Abstract][Full Text] [Related]
3. Antifungal agents: an overview. Part II. Gupta AK; Sauder DN; Shear NH J Am Acad Dermatol; 1994 Jun; 30(6):911-33; quiz 934-6. PubMed ID: 7619094 [TBL] [Abstract][Full Text] [Related]
5. Current therapy of dermatophytosis. Degreef HJ; DeDoncker PR J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S25-30. PubMed ID: 8077504 [TBL] [Abstract][Full Text] [Related]
6. New and prospective developments in antifungal drugs. Cauwenbergh G Acta Derm Venereol Suppl (Stockh); 1986; 121():147-53. PubMed ID: 3012922 [TBL] [Abstract][Full Text] [Related]
7. The use of systemic antimycotics in dermatotherapy. Niewerth M; Korting HC Eur J Dermatol; 2000 Mar; 10(2):155-60. PubMed ID: 10694319 [TBL] [Abstract][Full Text] [Related]
8. Dermatophytosis: the management of fungal infections. Gupta AK; Ryder JE; Chow M; Cooper EA Skinmed; 2005; 4(5):305-10. PubMed ID: 16282753 [TBL] [Abstract][Full Text] [Related]
10. Terbinafine. An update of its use in superficial mycoses. McClellan KJ; Wiseman LR; Markham A Drugs; 1999 Jul; 58(1):179-202. PubMed ID: 10439936 [TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Del Rosso JQ J Am Osteopath Assoc; 1997 Jun; 97(6):339-46. PubMed ID: 9232944 [TBL] [Abstract][Full Text] [Related]
12. Azole Resistance in Dermatophytes: Prevalence and Mechanism of Action. Ghannoum M J Am Podiatr Med Assoc; 2016; 106(1):79-86. PubMed ID: 26895366 [TBL] [Abstract][Full Text] [Related]
13. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Van Cutsem J; Van Gerven F; Janssen PA Rev Infect Dis; 1987; 9 Suppl 1():S15-32. PubMed ID: 3027843 [TBL] [Abstract][Full Text] [Related]
14. The treatment of dermatophytosis: safety considerations. Smith EB J Am Acad Dermatol; 2000 Nov; 43(5 Suppl):S113-9. PubMed ID: 11044286 [No Abstract] [Full Text] [Related]
15. [Antimycotic therapy in clinical practice]. Schaffner A Schweiz Med Wochenschr; 1991 Sep; 121(39):1413-8. PubMed ID: 1925472 [TBL] [Abstract][Full Text] [Related]
16. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. Korting HC; Schöllmann C J Dtsch Dermatol Ges; 2009 Jan; 7(1):11-9, 11-20. PubMed ID: 18479501 [TBL] [Abstract][Full Text] [Related]
17. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. Del Rosso JQ; Kircik LH J Drugs Dermatol; 2013 Nov; 12(11 Suppl):s165-71. PubMed ID: 24196340 [TBL] [Abstract][Full Text] [Related]